**Name of Journal:** *World Journal of Hepatology*

**Manuscript NO:** 68138

**Manuscript Type:** REVIEW

**Metabolic and nutritional triggers associated with increased risk of liver complications in SARS-CoV-2**

de Jesus RP *et al*. Nutrition and liver complicationsin SARS-CoV-2

Rosangela Passos de Jesus, Jozélio Freire de Carvalho, Lucivalda Pereira Magalhães de Oliveira, Carla de Magalhães Cunha, Thaisy Cristina Honorato Santos Alves, Sandra Tavares Brito Vieira, Virginia Maria Figueiredo, Allain Amador Bueno

**Rosangela Passos de Jesus, Lucivalda Pereira Magalhães de Oliveira, Carla de Magalhães Cunha, Thaisy Cristina Honorato Santos Alves, Sandra Tavares Brito Vieira,** Postgraduate Program in Food, Nutrition and Health at the School of Nutrition of the Federal University of Bahia, Salvador 40.110-150, Bahia, Brazil

**Jozélio Freire de Carvalho,** Institute of Health Sciences, Federal University of Bahia, Salvador 40231-300, Bahia, Brazil

**Thaisy Cristina Honorato Santos Alves,** Institute of Life Sciences, State University of Bahia, Salvador 41.150-000, Bahia, Brazil

**Virginia Maria Figueiredo,** Department of Gastroenterology, IPEMED, Ipemed Faculty of Medical Sciences, Salvador 40170-110, Bahia, Brazil

**Allain Amador Bueno,** College of Health, Life and Environmental Sciences, University of Worcester, Worcester WR2 6AJ, United Kingdom

**Author contributions:** All authors have contributed to conceptualization, literature appraisal, data gathering and original draft preparation; de Jesus RP, de Carvalho JF, Figueiredo VM and Bueno AA contributed to the final considerations, conclusions and final version of the manuscript; all authors have read and agreed to the published version of the manuscript.

**Corresponding author: Jozélio Freire de Carvalho, MD, PhD, Adjunct Professor,** Institute of Health Sciences, Federal University of Bahia, Av. Reitor Miguel Calmon, s/n - Canela, Salvador 40231-300, Bahia, Brazil. jotafc@gmail.com

**Received:** May 13, 2021

**Revised:** July 28, 2021

**Accepted:** December 22, 2021

**Published online:** January 28, 2022

**Abstract**

Obesity, diabetes, cardiovascular and respiratory diseases, cancer and smoking are risk factors for negative outcomes in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which can quickly induce severe respiratory failure in 5% of cases. Coronavirus disease-associated liver injury may occur during progression of SARS-CoV-2 in patients with or without pre-existing liver disease, and damage to the liver parenchyma can be caused by infection of hepatocytes. Cirrhosis patients may be particularly vulnerable to SARS-CoV-2 if suffering with cirrhosis-associated immune dysfunction. Furthermore, pharmacotherapies including macrolide or quinolone antibiotics and steroids can also induce liver damage. In this review we addressed nutritional status and nutritional interventions in severe SARS-CoV-2 liver patients. As guidelines for SARS-CoV-2 in intensive care (IC) specifically are not yet available, strategies for management of sepsis and SARS are suggested in SARS-CoV-2. Early enteral nutrition (EN) should be started soon after IC admission, preferably employing iso-osmolar polymeric formula with initial protein content at 0.8 g/kg per day progressively increasing up to 1.3 g/kg per day and enriched with fish oil at 0.1 g/kg per day to 0.2 g/kg per day. Monitoring is necessary to identify signs of intolerance, hemodynamic instability and metabolic disorders, and transition to parenteral nutrition should not be delayed when energy and protein targets cannot be met *via* EN. Nutrients including vitamins A, C, D, E, B6, B12, folic acid, zinc, selenium and ω-3 fatty acids have in isolation or in combination shown beneficial effects upon immune function and inflammation modulation. Cautious and monitored supplementation up to upper limits may be beneficial in management strategies for SARS-CoV-2 liver patients.

**Key Words:** COVID-19; SARS-CoV-2; Enteral nutrition; Parenteral nutrition; Hepatic failure

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** de Jesus RP, de Carvalho JF, de Oliveira LPM, Cunha CM, Alves TCHS, Vieira STB, Figueiredo VM, Bueno AA. Metabolic and nutritional triggers associated with increased risk of liver complications in SARS-CoV-2. *World J Hepatol* 2022; 14(1): 80-97

**URL:** https://www.wjgnet.com/1948-5182/full/v14/i1/80.htm

**DOI:** https://dx.doi.org/10.4254/wjh.v14.i1.80

**Core Tip:** Coronavirus disease-associated liver injury may occur in the progression of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with or without pre-existing liver disease. Patients with cirrhosis-associated immune dysfunction are particularly vulnerable. Strategies for management of sepsis and SARS are suggested in SARS-CoV-2 for intensive care patients, including early enteral nutrition soon after intensive care unit admission. Transition to parenteral nutrition should not be delayed when energy and protein targets cannot be met via EN. In outpatient settings, micronutrient and ω-3 fatty acids have shown beneficial effects upon immune function and inflammation modulation and may be beneficial in management for SARS-CoV-2 liver patients.

**INTRODUCTION**

In December 2019 a new viral infection was identified and observed to quickly induce severe respiratory failure. Its aetiological agent was described as a new betacoronavirus, responsible for inducing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), distinct from SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV). The disease spread extremely quickly around the globe, and the World Health Organization declared in March 2020 a pandemic[1]. It is believed that the SARS-CoV-2 may have mutated in wild sources including bats and snakes, and passed onto humans through direct contact, including their consumption, or indirect contact, for example exposure to faeces[1]. Anthroponotic transmission occurs mainly through saliva droplets, aerosols and through direct or close physical contact. Measures aimed at blocking droplets and aerosols such as efficient face covering, social distancing and hand and surface cleaning are imperative in reducing transmission[2].

Recent studies have described the angiotensin-converting enzyme receptor (ECA2) as a gateway for viral penetration into the host cells[3]. The ECA2 receptor is abundant in lung alveolar cells, which explains the significant pulmonary component of this infection. The gastrointestinal tract, heart and blood vessels are also target organs[4].

Around 81% of patients with coronavirus disease 2019 (COVID-19) infection will develop mild or mild to moderate disease. However, a study examining over 70000 cases in China showed that evolution to more severe forms is prone to occur in the elderly and in individuals suffering with comorbidities, such as systemic arterial hypertension, type 2 diabetes mellitus, heart disease, obesity, smoking, chronic pulmonary disease and cancer. Children are not statistically present as a risk group[5], and the male gender may be a potential risk factor[6]. Severe cases will account for approximately 14% of infected patients, who often need mechanical ventilation and present high mortality rates, reaching 80% within the severe case category. The overall risk of mortality in the general population varies from less than 1% to 3%[7].

**CLINICAL AND HEPATOLOGICAL ASPECTS OF SARS-COV-2**

A recent study recruiting 745 patients suffering with chronic liver disease and diagnosed with SARS-CoV-2 showed that cirrhosis was strongly associated with worsened outcomes, and of the 150 patients who died during the study, 82% had a diagnosis of cirrhosis. Although in that study the most common cause of death was infection-associated lung injury, and in only 19% of cases the primary cause of death was liver failure, such findings suggest that cirrhosis and its consequent immune dysfunction are potential facilitators of lung injury[8].

Hyperglycaemia, a metabolic disarrangement observed not only in type 2 diabetes but also in other conditions characterized by an important pro-inflammatory background, such as cardiovascular disease, hepatic steatosis, cancer and chronic respiratory disease, including respiratory disease induced by smoking, is known to impair the immune response and consequently lead to a worsened clinical evolution in SARS-CoV-2 patients[9]. Hyperglycaemia is a common feature of severe SARS-CoV-2 infection, usually induced by glucocorticoid hypersecretion associated with metabolic stress, and manifested in approximately 51% of cases[10]. The hyperglycaemia observed in severe cases has also been associated with transient impairment of pancreatic islet cell function[11]. Hyperglycaemia should not be neglected in SARS-CoV-2 therapies as it can induce additional immune suppression.

The presence of metabolic disturbances, inflammation and exacerbated oxidative stress are features associated with a rapid clinical deterioration in SARS. Although all populational groups can be affected by the viral disease, the elderly and patients with underlying clinical conditions, especially obesity and type 2 diabetes mellitus, are more vulnerable and are at greater risk of developing the more severe forms of SARS-CoV-2[12].

Individuals with obesity present a range of metabolic disturbances that facilitate worsened clinical outcomes, including alterations in different stages of their innate and adaptive immune response, a state of mild chronic inflammation, chronically higher levels of pro-inflammatory adipokines and lower levels of anti-inflammatory adipokines, and a strong association with type 2 diabetes. It is known that such unfavourable biochemical environment contributes to immune dysregulation and has been described as an important determinant in the severity of viral influenza infection[13,14]. Chronic inflammation associated with obesity jeopardizes macrophage activation by antigen presentation and pro-inflammatory cytokine synthesis[13]. In addition, B and T cell response are attenuated in obesity, contributing to increased susceptibility and delayed resolution of viral infection[13,15]. A recent study that examined the medical records of 37121 patients diagnosed with SARS-CoV-2 showed that age, the male gender and body mass index were unadjusted risk factors for disease severity[16].

A meta-analysis covering 46248 patients and examining the prevalence of comorbidities and underlying diseases in SARS-CoV-2 patients showed that the most prevalent comorbidities were arterial hypertension (17%), diabetes (8%), cardiovascular diseases (5%) and diseases of the respiratory tract (2%). Statistical analysis of each subgroup demonstrated that the presence of comorbidities in SARS-CoV-2 patients may increase the risk for greater severity and unfavourable clinical outcomes[17]. A diagnosis of diabetes was associated with a more severe clinical evolution (19.3%) when compared to non-diabetic individuals (11%) in severe case patients. The worsened clinical evolution cases showed more comorbidities including chronic obstructive pulmonary disease (4.8%), coronary heart disease (10.4%) and hypertension (38.7%). It has also been shown that hyperglycaemia at SARS-CoV-2 admission was associated with more severe evolution and higher mortality[18].

Some clinical and observational studies have described a “cytokine storm” in SARS-CoV-2 infection, which is characterised by significantly exacerbated systemic inflammation and immune dysfunction[19,20]. A study found that the pro-inflammatory cytokines related to macrophage function, mainly interleukin (IL) 6, IL-10 and tumour necrosis factor-α, increase significantly in most severe cases, in relation to cases of lesser intensity. Meanwhile, IL-6 levels remain high even in patients who have had moderate SARS-CoV-2 infection[19].

A meta-analysis evaluated clinical data obtained from 10 studies with 1995 cases in total and found that the immunological response of the patients included in the study was consistent with viral respiratory tract infection: 64.5% of patients showed lymphocytopenia, 29.4% leukocytopenia, 44.3% increased C reactive protein (CRP) and 28.3% showed increased lactate dehydrogenase (LDH)[20]. Furthermore, patients with more severe clinical presentation showed on hospital admission significantly increased inflammatory markers including CRP, ferritin, alanine aminotransaminase (ALT), aspartate aminotransferase (AST), LDH, gamma-glutamyl transferase (gamma-GT), as well as hypoalbuminemia, lymphocytopenia, neutropenia and eosinopenia[19-21].

Patients with chronic liver disease, particularly cirrhosis, show multiple mechanisms of immune dysfunction that together can increase the vulnerability to infection and an inadequate inflammatory response, defined as cirrhosis-associated immune dysfunction[22,23]. Elevation of transaminases and other biomarkers of liver dysfunction are common in SARS-CoV-2 patients, occurring in approximately 15% to 65% of cases. Abnormalities in liver biochemistry are commonly observed in SARS-CoV-2 patients regardless of the presence or not of pre-existing liver disease. However, the mechanisms underlying the impact of COVID-19 infection on liver function are not fully understood and may be multifactorial[24,25].

COVID-associated liver injury is defined as any liver injury that occurs in SARS-CoV-2 progression and treatment in patients with or without pre-existing liver disease. Generally, 2% to 11% of SARS-CoV-2 patients show underlying liver disease, and 14% to 53% show elevated AST and ALT[26]. Damage to the liver parenchyma in SARS-CoV-2 patients can be caused directly by infection of liver cells, once the ACE2 protein is expressed in hepatocytes and cholangiocytes[26,27]. Viral binding to ACE2 allows the virus to penetrate hepatocytes, inducing cytokine activation, apoptosis and necrosis, with resulting liver damage[28]. However, in addition to COVID as primary cause of liver disease, it is clinically important to note that pharmacotherapies including macrolide or quinolone antibiotics and steroids can also induce liver damage[29].

A study recruiting 1099 SARS-CoV-2 patients showed that 23.7% of the cohort had some pre-existing liver disease, including hepatitis B infection, non-alcoholic fatty liver disease and alcohol-related liver disease[30]. Hepatitis B was the most prevalent disease, identified in 2.1% of that sample population, with the majority of those patients presenting a more severe SARS-CoV-2 clinical evolution. Other studies have found hepatitis B to be more frequent in male individuals and in patients taking a worsened clinical outcome[26,29,31].

However, a recent retrospective study assessing the clinical presentation and specific biomarkers of 158 hospitalized SARS-CoV-2 patients showed that 42.4% of the cohort had elevated AST, ALT, alkaline phosphatase (AP), gamma-GT and total bilirubin at admission, and that 31.6% of the patients developed liver biomarker abnormalities in the course of their hospitalization. The liver changes were correlated with the oxygenation index, and at the time of discharge 40.5% of the patients were still showing abnormal liver biomarkers. In addition, factors such as younger age, hypertension and lymphocytopenia were independent risk factors for the persistence of abnormal liver markers during hospitalization[32]. A study carried out with 288 patients hospitalized for COVID-19 and previously established chronic liver disease caused mainly by viruses, metabolic fatty liver disease and alcohol intake, showed that from the 43 patients diagnosed with cirrhosis, 57% of them had the disease decompensated at the time of admission for SARS-Cov-2, and that mortality rate was extremely high in those patients, particularly in those with Child-Pugh cirrhosis score of ≥ 9[33].

Patients diagnosed with COVID-19 confirmed by computed tomography during the subclinical phase, that is, before the onset of symptoms, had a significantly lower incidence of AST abnormality than patients diagnosed after the onset of symptoms[34]. In addition, COVID-19 can worsen underlying chronic liver disease, inducing disease decompensation and acutely exacerbated chronic liver failure, a condition associated with high mortality rate. Recently, Cai *et al*[35] proposed a classification for the various typical liver test abnormalities found in SARS-CoV-2 patients. The study defined three patterns of injury based on ALT, AST, gamma-GT, AP and total bilirubin: first category: hepatocellular lesion usually progressing with predominant elevation of AST and ALT; second category: Cholestatic-type lesion with predominantly elevated gamma-GT and AP; and third category: mixed injury associated with an increase in all hepatocellular markers. It was observed that the presence of abnormalities in liver tests at hospital admission significantly increased the risk of severe pneumonia in the studied population, especially among those with hepatocellular or mixed lesions[35].

The SARS-CoV-2 virus was detected by *in situ* hybridization in 68% of liver sample biopsies of 48 patients who died of severe lung disease attributed to the infection[36]. Histological examination also identified abnormalities in intrahepatic vascular structures, mainly portal and sinusoidal microthrombosis (100% of cases), macrovesicular steatosis (50%), mild portal inflammation (66%) and portal fibrosis. The finding of steatosis was predominant in patients with obesity and overweight. The study of Sonzogni *et al*[36] reinforces the hypothesis that disturbances in the coagulation cascade or impaired blood circulation or endothelial damage may trigger mechanisms in the pathogenesis of COVID-19 damage in the liver.

**NUTRITION AND CHRONIC LIVER DISEASE IN THE CONTEXT OF SARS-COV-2**

Chronic consumption of westernised diets (WD), which typically contain high levels of saturated fats and simple carbohydrates, contributes to the incidence of obesity and type II diabetes, which are conditions positively associated with the more severe forms of SARS-CoV-2 infection and higher mortality rate[37]. WD chronic consumption activates the innate immune system and compromises adaptive immunity, leading to chronic inflammation and impaired host immune defence against the virus[12]. In addition to impaired innate immunity, WD chronic consumption is known to inhibit T and B function in the adaptive immune system, potentially *via* increased oxidative stress[12,38].

WD are also associated with intestinal dysbiosis and unbalanced pro/anti-inflammatory-associated T function in the intestine, with consequent immune incompetence, intestinal and extra-intestinal inflammation. The immune imbalance resulted from gut dysbiosis can worsen infectious conditions and dysregulate metabolic pathways, increasing the risk for liver complications[37,39-41].

A study evaluated a dataset from 188 countries to identify effects of diet, malnutrition and obesity upon the global SARS-CoV-2 cases and their underlying circumstances, as well as mortality and recovery rates[40]. The results suggest that populations that consume predominantly WD showed higher SARS-CoV-2-associated mortality. Such findings may be explained by the disturbances induced by WD upon intestinal microbiota, affecting the phenotype and function of intestinal T CD4+ cells, which can result in greater susceptibility to infections[41].

In summary, individuals suffering with systemic inflammation induced by overweight or obesity and associated chronic diseases such as diabetes, heart, kidney, liver and lung diseases, are more likely to develop the most severe forms of SARS-CoV-2. Therefore, a broader access to nutritional knowledge to the wider population, with the subsequent adoption of healthier eating behaviours, are Public Health priorities. Populations in general need to be made aware that healthier eating behaviours are important protective factors against long-term complications and negative outcomes in SARS-CoV-2[12]. In general, nutritional recommendations ought to focus on reduction of saturated fats and simple sugars, combined with the adequate consumption of dietary fibre, whole grains, polyunsaturated fats, and antioxidant and bioactive nutrients that enhance immune function[12,42]. Figure 1 illustrates the main factors associated with the pathophysiology of SARS-CoV-2 disease that contribute to the most severe forms of the infection.

**NUTRITIONAL THERAPIES FOR PATIENTS WITH LIVER COMPLICATIONS**

Nutritional therapy (NT) recommendations for critically ill patients with a diagnosis of acute liver failure (ALC) or acute-on-chronic liver failure (ACLF) follow the same principles as NT aimed at critically ill patients. Early enteral nutrition (EN) is recommended, starting with trophic rates (10 mL/h to 20 mL/h) containing approximately 15 kcal/kg BW per day to 20 kcal/kg BW per day, due to increased risk of diet intolerance secondary to mesenteric ischaemia, vomiting, or adynamic ileus, which may occur during the first week of hospitalization[43]. Energy content can be gradually increased up until reaching 30 kcal/kg BW per day to 35 kcal/kg BW per day[44]. In severely ill ALC or ACLF patients who are malnourished, EN alone or associated with parenteral nutrition (PN) should be started immediately[44]. The enteral route should be preferred whenever possible, but PN should be initiated if there is a need to reach nutritional requirements, especially when EN is not safe or tolerated[43,44,45].

Continuous EN is recommended over bolus infusion to reduce the incidence of diarrhoea, improve glycaemic control, and reduce healthcare worker interaction, thereby limiting their exposure to SARS-CoV-2[43]. A daily prescription of 1.2 g protein/kg BW is recommended for patients with liver disease without malnutrition, and 1.5 g of protein for malnourished or sarcopenic patients. However, in patients with severe hyperacute disease with hepatic encephalopathy and high arterial ammonia, or at risk of developing cerebral oedema, protein nutritional support can be delayed for 24 h to 48 h until the hyperammonaemia is controlled[44]. Additionally, the use of standard formulae may be suggested as no robust scientific evidence appears to be available as yet on the proven benefits of formulae supplemented with branched chain amino acids in critically ill patients with liver disease[44,45].

**NUTRITIONAL THERAPIES FOR SARS-COV-2 PATIENTS WITH LIVER COMPLICATIONS**

As NT guidelines for SARS-CoV-2 in intensive care specifically are not yet available, nutrient recommendations are centred on the principles of nutrition in intensive care, which must be adapted to the patient considering their clinical conditions and associated complications. Therefore, as the patient with severe SARS-CoV-2 generally presents manifestations similar to patients admitted to intensive care unit (ICU) with pulmonary impairment, the employment of strategies for the management of conditions such as sepsis and severe acute respiratory distress syndrome is suggested[46].

Decision making regarding the initiation and progression of NT, as well as the selection of the feeding route and the type of diet during hospitalization of moderate and severe SARS-CoV-2 patients, need to consider the patient’s clinical presentation[47]. EN is less expensive and inherently presents overall lower risks for the patient than PN, in addition to mimicking a more physiological form of feeding. However, both types of nutritional administration can have adverse effects and long-term complications[48]. Early EN shows several benefits including increased splanchnic blood flow, maintained enterocyte barrier and stimulated immunity. Although current evidence suggests that the use of early EN in critically ill patients results in the preservation of splanchnic blood flow, high calorie EN can induce complications in patients with hypovolemic shock. However, it has been shown that EN infusion at low dosage to allow for intestinal trophism is associated with better clinical outcomes in critically ill patients[49].

Thus, it is recommended that EN should be started as soon as possible after admission to ICU, preferably employing an iso-osmolar standard polymeric formula designed for gradual administration, starting with low flow and evolving according to gastrointestinal tolerance. Monitoring is necessary to identify signs of intolerance, hemodynamic instability and metabolic disorders. EN with intragastric location can be safely provided even for patients positioned in pronation and oxygenation by extracorporeal membrane[46].

Sepsis is associated with an initial state of systemic and hypermetabolic inflammation, with subsequent worsening of immunosuppression characterized by apoptosis and lymphocyte depletion. This later phase is also characterised by reduced capacity of monocytes and macrophages to release pro-inflammatory cytokines, further facilitating infection[50]. SARS-CoV-2 patients who develop sepsis, with or without liver complications, can benefit from early EN in combination with supplementary PN as ideal strategy to reach at least 80% of calorie needs by the third day of hospitalization. It is also recommended that protein be administered initially at low dosage (0.8 g/kg per day), progressively increased until reaching 1.3 g/kg per day after control and resolution of sepsis[48].

The transition to PN should not be delayed when it is not possible to reach energy and protein targets through the gastrointestinal tract or where contraindications for EN exist. Such patients may present intolerance to EN, characterized by classical clinical manifestations such as nausea, vomiting and abdominal distention, which evidences the need for concomitant PN administration. Another factor that may limit EN in critically ill SARS-CoV-2 patients is the placement of the post-pyloric tube, which would involve an additional aerosol generation procedure. In addition, the use of non-invasive positive pressure ventilation can prevent the use of feeding tube due to the difficulty of establishing an efficient seal with a comfortable fit[46,51].

The indication of PN for SARS-CoV-2 patients is common in intensive care, which must follow the principles and recommendations for NT in critically ill patients[46,51]. However, frequently in SARS-CoV-2 patients there is a need to maintain PN for extended periods, which unfortunately increases the risk of metabolic disturbances and liver disease associated with intravenous (IV) infusion of nutrients. Thus, the development of hyperglycaemia, hyperlipidaemia and fatty liver disease must be considered when PN as exclusive route is used for extended period[48].

The reduction in luminal content and the absence of trophic stimuli from the intestine to the liver induced by PN may contribute to PN-associated liver disease (PNALD), or liver disease associated with intestinal failure[52]. PNALD, in addition to hyperglycaemia, steatosis and dyslipidaemia, can also induce liver fibrosis or cirrhosis if PN exclusive use is prolonged, especially without concomitant EN[53]. Although there is variability, PN-associated cholestasis can induce elevations in transaminases, AP, gamma-GT and conjugated bilirubin, which is similar to other cholestatic diseases and therefore should be investigated for their differential diagnosis. Considering the adverse effects associated with prolonged PN, EN may be relevant in preventing liver disease as to preserve the integrity of the intestinal mucosa and maintenance of the liver gut axis[52].

Several mechanisms can explain hepatic changes induced by PN, including deterioration of the intestinal mucosa, facilitated bacterial translocation through the intestinal epithelium, inflammation, and hepatic endotoxicity. It is believed that the lack of activation of enterocyte receptors by luminal agonists, attributed to the absence of enteral feeding, may decrease signalling to the liver *via* portal circulation, interrupting the gut liver axis cross-communication[52]. The reduced blood flow to the small intestine and portal vein that occurs in PN is associated with lowered liver mononuclear cell counts, potentially contributing to hepatocellular dysfunction[54].

Hepatobiliary receptors, including the farnesoid X receptor (FXR) and the Takeda G protein-coupled receptor 5, appear to have an important role on PNALD pathogenesis. Reduced activity of the human orthologous fibroblast growth factor-19 (FGF19), which exerts hepatoprotective action, as well as decreased activity of the intestinal trophic factor glucagon-like peptide-2, may be associated with PN. FXR signalling is a pathway that regulates the secretion of FGF19, a protein that modulates cholesterol 7 alpha-hydroxylase 1, which in turn limits the synthesis of bile acids. PN has been shown to inhibit this signalling pathway, inducing changes in bile acid metabolism, hepatocyte apoptosis, hepatocellular injury and liver fibrosis[53].

Hyperglycaemia is commonly observed in EN and PN and has been associated with increased risk of clinical complications and mortality during hospitalization[55]. To date, there are no specific guidelines that recommend glycaemic targets and effective strategies for the management of EN or PN-associated hyperglycaemia in SARS-CoV-2 patients. However, it is known that the elevation of inflammatory markers such as IL-6, CRP, ferritin and D-dimer are more persistent in hyperglycaemic patients during hospitalization for SARS-CoV-2. In addition, patients with hyperglycaemia or diagnosed with diabetes are at higher risk for the progression of SARS-CoV-2 disease severity when compared with normoglycaemic and those without a diagnosis of diabetes[56,57]. Glycaemic control in SARS-CoV-2 patients must include optimization of the carbohydrate content and continuous IV insulin to offer the best possible glycaemic control[56].

The source of lipids in PN is often derived from soybean oil, a source of ω-6 polyunsaturated fatty acids (PUFAs). Arachidonic acid is bioconverted to prostaglandins, thromboxanes and leukotrienes of series 2 and 4, which are pro-inflammatory and may contribute to the increased incidence of cholestasis, steatosis, sepsis, changes in neutrophil function and positive regulation of matrix metalloproteinases (MMPs)[58]. Preservation of the matrix is ​​essential for reducing the progression of liver disease, and it is known that increased MMP activity can cause damage to the liver parenchyma[59]. It is therefore recommended that the PN prescription in SARS-CoV-2 should prioritize lipid emulsions enriched with fish oil, with doses of approximately 0.1 g/kg per day to 0.2 g/kg per day[60].

SARS-CoV-2 patients with history of liver disease require attention to the provision of NT as they may present impaired digestion and absorption of nutrients, altered protein metabolism, insulin resistance and previous nutritional deficiency. Such manifestations can negatively influence tolerance to NT, posing an additional obstacle for the daily nutritional requirements[61,62]. Table 1 presents the summary of the main general guidelines for NT for patients with liver disease or liver disorders developed in the clinical course of SARS-CoV-2 severe infection.

**NUTRITION AND IMMUNE RESPONSE IN SARS-COV-2**

The link nutrition — immune response is very well established: malnutrition is a risk factor for respiratory infection[63]. Previous scientific evidence shows that vitamins A, C, D, E, pyridoxine (B6), cyanocobalamin (B12), and folic acid, trace elements including zinc, iron, selenium, magnesium and copper, as well as the functionally essential ω-3 PUFAs eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids, all have a paramount effect on immune function[64-67]. Evidence shows that the regular intake of functional foods containing anti-inflammatory and immunomodulatory nutrients and bioactive agents are associated with optimum immune function[12,42,68].

Nutritional recommendations for SARS-CoV-2 therapies specifically are not yet available. However, as the SARS-CoV-2 virus shares some functional similarities with other coronaviruses identified before the current pandemic, it may be expected that the scientific evidence gathered previously may be relevant for COVID-19. A summary of the main scientific evidence available is presented in Table 2.

***Vitamins***

A recent narrative review encompassing 204 studies summarised the beneficial effects of vitamins A and E against COVID-19, mainly through their antioxidant and immunomodulatory effects, as well as activation of innate immunity and local paracrine signalling[69]. Furthermore, the beneficial effects of thiamine, vitamin C and vitamin D in respiratory diseases similar to SARS-CoV-2 and sepsis have also been identified[69]. Despite the current lack of clinical trials investigating the effects of vitamin supplementation on SARS-CoV-2, when considering pathophysiological pathways related to viral replication and the immune system, the scientific evidence available to date encourages the recommendation for said nutrients in supplemental form in the event of nutrient deficiency.

Vitamin A and its plant-derived precursor beta-carotene are often referred to as “anti-infective agents”. Studies have shown a higher risk of measles and worsened outcomes in vitamin A deficiency. Vitamin A supplementation is believed to have reduced morbidity and mortality from measles, diarrhoea, pneumonia, HIV and malaria[70]. Vitamin A is known to possess antiviral properties in measles, reducing viral replication possibly due to its role in innate immunity[71]. Regarding coronavirus specifically, one study identified reduced effectiveness of coronavirus vaccine in cattle when in conditions of vitamin A deficiency[72].

Regarding the B group of vitamins, studies have shown that the combination of vitamin B2 (riboflavin) and ultraviolet radiation was able to reduce the viral load of MERS-CoV in human plasma products[73]. Vitamin B3 (nicotinamide) has shown bactericidal properties against *Staphylococcus aureus*[74]. Nicotinamide has been associated with reduced inflammation in mechanical ventilation-associated pneumonia, mainly attributed to reduction in neutrophilic migration, although hypoxemia was a negative outcome identified[75].

A recent study using *in silico* technology simulated the binding of the main protease (Mpro) of the coronavirus with a range of molecules that could potentially possess antiviral and or therapeutic effects against SARS-CoV-2[76]. The results showed that the chemical structure of cyanocobalamin (B12) and nicotinamide presented some interaction with the Mpro active site. Cyanocobalamin and nicotinamide were ranked in the 4th and 6th position, respectively, in the list of molecules tested, placed after the antivirals ribavirin and telbivudine. The authors suggest that the combined use of ribavirin, telbivudine, cyanocobalamin and nicotinamide could be tested as a potential treatment for SARS-CoV-2. A study that investigated the effects of cyanocobalamin in hepatitis C patients showed a sustained virological response (SVR) when this vitamin was added to standard antiviral therapy, suggesting that cyanocobalamin supplementation may be an independent factor associated with SVR in difficult-to-treat genotype (genotype 1) hepatitis C and in those with a higher baseline viral load[77].

Ascorbic acid has been studied widely, and previous research has reported beneficial effects in the prevention and treatment of coronavirus infections[78]. Ascorbic acid has also been associated with antihistamine effects, which alleviate some cold symptoms[79]. A clinical study carried out with 19357 individuals without pre-existing lung diseases investigated the association between plasma vitamin C levels and the risk of respiratory diseases after a three-year follow-up. The results showed that higher vitamin C plasma levels, which is an indicator of greater consumption of fruit and vegetables, were related to lower risk for chronic respiratory diseases, including pneumonia. The authors suggest that a daily intake of 3 to 5 servings of fruit and vegetables may provide adequate intake of vitamin C and promote significant health benefits for the general population[80].

Vitamin D, with its important hormonal actions, acts on several components of the immune system, including the synthesis of cathelicidin, an endogenous antimicrobial peptide. A meta-analysis covering over 11000 individuals showed that vitamin D supplementation, even when its serum levels are adequate, can reduce by 25% (adjusted OR: 0.75; 95%CI: 0.60-0.95) the chance of contracting infections of the upper and lower airways, with a more expressive result (70% of cases) for those with baseline levels of 25-hydroxyvitamin D (25(OH)D) below 25 nmol/L (adjusted OR: 0.30; 95%CI: 0.17-0.53)[65]. A systematic review of 42 clinical studies testing the effects of vitamins, minerals, nutraceuticals and probiotics on immunological markers of patients with viral and respiratory infections showed that vitamins A and D were associated with better outcomes, an effect that was more predominant in populations deficient in those nutrients[67].

A recent narrative review discussed the relationship between vitamin D deficiency and the risk for influenza and COVID-19, and further emphasized the increased risk in aged individuals and in those suffering with chronic comorbidities[81]. Their recommendations to reduce the risk of influenza and COVID-19 infections involve 10,000 IU vitamin D3 supplementation daily for a few weeks to rapidly increase 25(OH)D serum levels. This period would be followed by a maintenance daily dose of 5000 IU to maintain 25(OH)D above 40 ng/mL to 60 ng/mL (equivalent to 100 nmol/L to 150 nmol/L). However, randomized clinical trials and large population studies must be conducted to evaluate the effectiveness of such recommendations.

Vitamin E, including α-tocopherol and tocotrienol, is a potent fat-soluble antioxidant found in significant concentration in immune cells. Some evidence suggests that the currently recommended vitamin E intake may be low, and that its supplementation above current dietary recommendations favoured immune function and reduced the risk of infection, especially in the elderly. Vitamin E contributes to T cell membrane integrity, signal transduction and cell division, and also indirectly by attenuating inflammatory mediators released by other immune cells. The modulation of immune function by vitamin E has clinical relevance, as it affects the host's susceptibility to infectious diseases and respiratory diseases such as asthma and pneumonia[68].

Vitamin E supplementation was found to have different responses upon the incidence of pneumonia when factoring smoking and levels of physical activity[82]. Vitamin E reduced the risk of pneumonia by 69% in participants who had lower exposure to smoking and performed more physical exercise. In the opposite direction however, vitamin E supplementation increased the risk of pneumonia by 68% in the individuals who had greater exposure to smoking and did not exercise. Interestingly, a study in calves has shown greater risk of coronavirus infection in the vitamin E-deficient animals[83]. Overall, such findings suggest that the effects of vitamin E supplementation upon pneumonia risk are likely to be positive but may not be uniform and therefore caution is recommended when supplementing, balancing benefit against risk.

***Trace elements***

Selenium deficiency has been associated with reduced immune response and greater virulence of some benign viruses[84]. An experimental study in birds showed that selenium supplementation associated with ginseng increased the immune response against avian coronavirus[85]. Selenium deficiency was associated with mutations in genomic RNA that can potentially influence the virulence of certain RNA viruses, such as influenza A virus[86]. Clinical benefits associated with the potential immunomodulatory effects of selenium supplementation have also been demonstrated in other viral infections, including HIV-1[87]. A randomized controlled study found that selenium supplementation reduced the viral load in HIV patients[88]. Lastly, a systematic review assessing the effects of mineral supplementation upon immunological markers in patients diagnosed with respiratory infections of viral origin showed that selenium and zinc had favourable immunomodulatory effects, improving the clinical evolution in viral respiratory infections[67].

It is known that the risk of developing pneumonia associated with mechanical ventilation is high, especially when the use of respirators is prolonged, as in the most severe cases of SARS-CoV-2. A randomized clinical study carried out with 99 critically ill patients investigated the effects of selenium infusion compared to isotonic saline for 10 d. Selenium infusion increased not only its serum levels but also the concentration of glutathione peroxidase-3, but it did not reduce the incidence of pneumonia or mortality of the critically ill patients evaluated[89]. In view of the evidence presented, there is a possibility that selenium levels may influence the clinical evolution of SARS-CoV-2, but such suggestion can only be confirmed or rejected through well-designed clinical research.

Zinc is the second most abundant trace element in the body; it is present in the cytoplasm as a cation and in the blood it is associated with metalloprotein[90]. It is an important trace element for cell maturity in both the innate and acquired immune systems, in addition to having antiviral properties. It has been shown that the replication of SARS-coronavirus, hepatitis C virus and influenza virus (H1N1) can be inhibited by zinc oxide or salt[90,91]. In addition, zinc supplementation in children diagnosed with measles reduced morbidity from pneumonia associated with this infection[92]. The antiviral properties of zinc are not yet well defined, but they are possibly related to the inhibition of viral binding to the mucosa, inflammation suppression, synthesis of antiviral interferon and inhibition of the enzyme necessary for viral replication[90,91].

Several clinical trials are currently being developed investigating the effectiveness of chloroquine as anti-coronavirus agent. It has been hypothesized that the mechanism of action of chloroquine may involve the induction of zinc uptake into the cytosol, a mechanism that could be associated with inhibition of the viral RNA polymerase inside the infected cell [90]. Future clinical trials shall explore any potentially synergistic role of zinc and chloroquine in SARS-CoV-2 patients.

***Essential fatty acids***

Essential fatty acid deficiency can result in late or insufficient resolution of inflammation, which can be a determining factor for the evolution of SARS-CoV-2 to the most severe forms, characterized by intense inflammation[63,93]. A meta-analysis assessing clinical studies that employed nutritional formulae containing EPA and DHA for patients with ARDS identified a significant improvement in blood oxygenation and a reduction in the need for mechanical ventilation, organ failure, ICU length of stay and mortality at 28 d of hospitalization[94]. Such results suggest an important effect of EPA and DHA in improving inflammation and lung injury, probably due to anti-inflammatory mediators including resolvins, protectins and maresines and others, which are derived from EPA and DHA[63,94].

**CONCLUSION**

Hyperglycaemia, a common feature of severe SARS-CoV-2 infection induced by glucocorticoid hypersecretion associated with metabolic stress, should not be neglected in SARS-CoV-2 therapies due to the additional risk of immune suppression. The unfavourable biochemical environment observed in obesity and diabetes contributes to immune dysregulation and has been described as an important determinant in SARS-CoV-2 outcomes.

COVID-associated liver injury often occurs in the evolution of SARS-CoV-2 into more severe stages and can affect patients with or without pre-existing liver disease. Furthermore, pharmacotherapies including macrolide or quinolone antibiotics and steroids can also induce liver damage. The presence and exacerbation of liver disease are directly associated with more negative outcomes in SARS-CoV-2.

NT guidelines for liver patients affected by SARS-CoV-2 in intensive care, specifically, are not yet available. For that reason, strategies for the management of conditions such as sepsis and severe acute respiratory distress syndrome are suggested. EN poses several advantages, namely lower cost, overall lower risk, preservation of splanchnic blood flow and intestinal trophism, and maintenance of enterocyte barrier. NE with intragastric location can be provided for patients positioned in pronation and oxygenation by extracorporeal membrane. An iso-osmolar standard polymeric formula designed for gradual administration with initial protein content at 0.8 g/kg per day progressively increasing up to 1.3 g/kg per day and enriched with fish oil at 0.1 g/kg per day to 0.2 g/kg per day is often recommended. Transition to PN should not be delayed when it is not possible to reach energy and protein targets through the gastrointestinal tract or where contraindications for EN exist. As prolonged PN may contribute to PNALD, EN should always be considered whenever possible. As EN or PN-associated hyperglycaemia is another factor to consider, glycaemic control in SARS-CoV-2 patients must include optimization of the carbohydrate content and continuous IV insulin to offer the best possible glycaemic control.

For patients who have not developed the more severe forms of SARS-CoV-2, the following recommendations can be made: (1) Optimal nutrient intake can help reduce the impact of SARS-CoV-2 and possibly limit the evolution to more severe forms; (2) Early health interventions in obesity, type 2 diabetes, heart, lung and liver disease are effective preventative strategies against SARS-CoV-2; (3) Supplementation with the micronutrients and omega-3 fatty acids described in the present study is a safe, effective and low-cost strategy to help stimulate optimal immune function; (4) Supplementation beyond the Recommended Dietary Allowance can be considered, but only within the upper safe limits (maximum tolerable intake — tolerable upper intake level — UL) for specific nutrients such as vitamins C and D; and (5) Public health authorities are encouraged to include nutritional strategies in their recommendations so that public health policies can assist in the efforts against respiratory diseases of viral origin.

**REFERENCES**

1 **Zhou P**, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD, Chen J, Luo Y, Guo H, Jiang RD, Liu MQ, Chen Y, Shen XR, Wang X, Zheng XS, Zhao K, Chen QJ, Deng F, Liu LL, Yan B, Zhan FX, Wang YY, Xiao GF, Shi ZL. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* 2020; **579**: 270-273 [PMID: 32015507 DOI: 10.1038/s41586-020-2012-7]

2 **Cook TM**. Personal protective equipment during the coronavirus disease (COVID) 2019 pandemic - a narrative review. *Anaesthesia* 2020; **75**: 920-927 [PMID: 32246849 DOI: 10.1111/anae.15071]

3 **Hoffmann M**, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA, Drosten C, Pöhlmann S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* 2020; **181**: 271-280.e8 [PMID: 32142651 DOI: 10.1016/j.cell.2020.02.052]

4 **Zhao Y**, Zhao Z, Wang Y, Zhou Y, Ma Y, Zuo W. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. 2020 Preprint. Available from: bioRxiv:2020.01.26.919985 [DOI: 10.1101/2020.01.26.919985]

5 **Wu Z**, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA* 2020; **323**: 1239-1242 [PMID: 32091533 DOI: 10.1001/jama.2020.2648]

6 **Wang D**, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA* 2020; **323**: 1061-1069 [PMID: 32031570 DOI: 10.1001/jama.2020.1585]

7 **Jordan RE**, Adab P, Cheng KK. Covid-19: risk factors for severe disease and death. *BMJ* 2020; **368**: m1198 [PMID: 32217618 DOI: 10.1136/bmj.m1198]

8 **Marjot T**, Moon AM, Cook JA, Abd-Elsalam S, Aloman C, Armstrong MJ, Pose E, Brenner EJ, Cargill T, Catana MA, Dhanasekaran R, Eshraghian A, García-Juárez I, Gill US, Jones PD, Kennedy J, Marshall A, Matthews C, Mells G, Mercer C, Perumalswami PV, Avitabile E, Qi X, Su F, Ufere NN, Wong YJ, Zheng MH, Barnes E, Barritt AS 4th, Webb GJ. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study. *J Hepatol* 2021; **74**: 567-577 [PMID: 33035628 DOI: 10.1016/j.jhep.2020.09.024]

9 **Stefan N**, Birkenfeld AL, Schulze MB. Global pandemics interconnected - obesity, impaired metabolic health and COVID-19. *Nat Rev Endocrinol* 2021; **17**: 135-149 [PMID: 33479538 DOI: 10.1038/s41574-020-00462-1]

10 **Chen N**, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* 2020; **395**: 507-513 [PMID: 32007143 DOI: 10.1016/S0140-6736(20)30211-7]

11 **Yang JK**, Lin SS, Ji XJ, Guo LM. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. *Acta Diabetol* 2010; **47**: 193-199 [PMID: 19333547 DOI: 10.1007/s00592-009-0109-4]

12 **Butler MJ**, Barrientos RM. The impact of nutrition on COVID-19 susceptibility and long-term consequences. *Brain Behav Immun* 2020; **87**: 53-54 [PMID: 32311498 DOI: 10.1016/j.bbi.2020.04.040]

13 **Luzi L**, Radaelli MG. Influenza and obesity: its odd relationship and the lessons for COVID-19 pandemic. *Acta Diabetol* 2020; **57**: 759-764 [PMID: 32249357 DOI: 10.1007/s00592-020-01522-8]

14 **Richard C**, Wadowski M, Goruk S, Cameron L, Sharma AM, Field CJ. Individuals with obesity and type 2 diabetes have additional immune dysfunction compared with obese individuals who are metabolically healthy. *BMJ Open Diabetes Res Care* 2017; **5**: e000379 [PMID: 28761653 DOI: 10.1136/bmjdrc-2016-000379]

15 **Ahn SY**, Sohn SH, Lee SY, Park HL, Park YW, Kim H, Nam JH. The effect of lipopolysaccharide-induced obesity and its chronic inflammation on influenza virus-related pathology. *Environ Toxicol Pharmacol* 2015; **40**: 924-930 [PMID: 26509733 DOI: 10.1016/j.etap.2015.09.020]

16 **Shauly-Aharonov M**, Shafrir A, Paltiel O, Calderon-Margalit R, Safadi R, Bicher R, Barenholz-Goultschin O, Stokar J. Both high and low pre-infection glucose levels associated with increased risk for severe COVID-19: New insights from a population-based study. *PLoS One* 2021; **16**: e0254847 [PMID: 34293038 DOI: 10.1371/journal.pone.0254847]

17 **Yang J**, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, Ji R, Wang H, Wang Y, Zhou Y. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. *Int J Infect Dis* 2020; **94**: 91-95 [PMID: 32173574 DOI: 10.1016/j.ijid.2020.03.017]

18 **Li X**, Xu S, Yu M, Wang K, Tao Y, Zhou Y, Shi J, Zhou M, Wu B, Yang Z, Zhang C, Yue J, Zhang Z, Renz H, Liu X, Xie J, Xie M, Zhao J. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. *J Allergy Clin Immunol* 2020; **146**: 110-118 [PMID: 32294485 DOI: 10.1016/j.jaci.2020.04.006]

19 **Chen G**, Wu D, Guo W, Cao Y, Huang D, Wang H, Wang T, Zhang X, Chen H, Yu H, Zhang X, Zhang M, Wu S, Song J, Chen T, Han M, Li S, Luo X, Zhao J, Ning Q. Clinical and immunological features of severe and moderate coronavirus disease 2019. *J Clin Invest* 2020; **130**: 2620-2629 [PMID: 32217835 DOI: 10.1172/JCI137244]

20 **Li LQ**, Huang T, Wang YQ, Wang ZP, Liang Y, Huang TB, Zhang HY, Sun W, Wang Y. COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. *J Med Virol* 2020; **92**: 577-583 [PMID: 32162702 DOI: 10.1002/jmv.25757]

21 **Ridruejo E**, Soza A. The liver in times of COVID-19: What hepatologists should know. *Ann Hepatol* 2020; **19**: 353-358 [PMID: 32425991 DOI: 10.1016/j.aohep.2020.05.001]

22 **Albillos A**, Lario M, Álvarez-Mon M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. *J Hepatol* 2014; **61**: 1385-1396 [PMID: 25135860 DOI: 10.1016/j.jhep.2014.08.010]

23 **Noor MT**, Manoria P. Immune Dysfunction in Cirrhosis. *J Clin Transl Hepatol* 2017; **5**: 50-58 [PMID: 28507927 DOI: 10.14218/JCTH.2016.00056]

24 **Youssef M**, H Hussein M, Attia AS, M Elshazli R, Omar M, Zora G, S Farhoud A, Elnahla A, Shihabi A, Toraih EA, S Fawzy M, Kandil E. COVID-19 and liver dysfunction: A systematic review and meta-analysis of retrospective studies. *J Med Virol* 2020; **92**: 1825-1833 [PMID: 32445489 DOI: 10.1002/jmv.26055]

25 **Singh S**, Khan A. Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Among Patients With Preexisting Liver Disease in the United States: A Multicenter Research Network Study. *Gastroenterology* 2020; **159**: 768-771.e3 [PMID: 32376408 DOI: 10.1053/j.gastro.2020.04.064]

26 **Zhang J**, Taylor EW, Bennett K, Saad R, Rayman MP. Association between regional selenium status and reported outcome of COVID-19 cases in China. *Am J Clin Nutr* 2020; **111**: 1297-1299 [PMID: 32342979 DOI: 10.1093/ajcn/nqaa095]

27 **Prins GH**, Olinga P. Potential implications of COVID-19 in non-alcoholic fatty liver disease. *Liver Int* 2020; **40**: 2568 [PMID: 32306495 DOI: 10.1111/liv.14484]

28 **Sansoè G**, Aragno M, Wong F. COVID-19 and Liver Cirrhosis: Focus on the Nonclassical Renin-Angiotensin System and Implications for Therapy. *Hepatology* 2021; **74**: 1074-1080 [PMID: 33524188 DOI: 10.1002/hep.31728]

29 **Xu L**, Liu J, Lu M, Yang D, Zheng X. Liver injury during highly pathogenic human coronavirus infections. *Liver Int* 2020; **40**: 998-1004 [PMID: 32170806 DOI: 10.1111/liv.14435]

30 **Su S**, Shen J, Zhu L, Qiu Y, He JS, Tan JY, Iacucci M, Ng SC, Ghosh S, Mao R, Liang J. Involvement of digestive system in COVID-19: manifestations, pathology, management and challenges. *Therap Adv Gastroenterol* 2020; **13**: 1756284820934626 [PMID: 32595762 DOI: 10.1177/1756284820934626]

31 **Thoresen M**, Wesche J. Doppler measurements of changes in human mammary and uterine blood flow during pregnancy and lactation. *Acta Obstet Gynecol Scand* 1988; **67**: 741-745 [PMID: 3250187 DOI: 10.1097/MEG.0000000000001811]

32 **Gan Q**, Gong B, Sun M, Cao Z, Zheng Y, Zhang Y, Wen P, Shen Y, Hong L, Hou T, Jia Y, Li W, Li H, Xie Q. A High Percentage of Patients Recovered From COVID-19 but Discharged With Abnormal Liver Function Tests. *Front Physiol* 2021; **12**: 642922 [PMID: 33815147 DOI: 10.3389/fphys.2021.642922]

33 **Sarin SK**, Choudhury A, Lau GK, Zheng MH, Ji D, Abd-Elsalam S, Hwang J, Qi X, Cua IH, Suh JI, Park JG, Putcharoen O, Kaewdech A, Piratvisuth T, Treeprasertsuk S, Park S, Wejnaruemarn S, Payawal DA, Baatarkhuu O, Ahn SH, Yeo CD, Alonzo UR, Chinbayar T, Loho IM, Yokosuka O, Jafri W, Tan S, Soo LI, Tanwandee T, Gani R, Anand L, Esmail ES, Khalaf M, Alam S, Lin CY, Chuang WL, Soin AS, Garg HK, Kalista K, Batsukh B, Purnomo HD, Dara VP, Rathi P, Al Mahtab M, Shukla A, Sharma MK, Omata M; APASL COVID Task Force, APASL COVID Liver Injury Spectrum Study (APCOLIS Study-NCT 04345640). Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study). *Hepatol Int* 2020; **14**: 690-700 [PMID: 32623632 DOI: 10.1007/s12072-020-10072-8]

34 **Shi H**, Han X, Jiang N, Cao Y, Alwalid O, Gu J, Fan Y, Zheng C. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. *Lancet Infect Dis* 2020; **20**: 425-434 [PMID: 32105637 DOI: 10.1016/S1473-3099(20)30086-4]

35 **Cai Q**, Huang D, Yu H, Zhu Z, Xia Z, Su Y, Li Z, Zhou G, Gou J, Qu J, Sun Y, Liu Y, He Q, Chen J, Liu L, Xu L. COVID-19: Abnormal liver function tests. *J Hepatol* 2020; **73**: 566-574 [PMID: 32298767 DOI: 10.1016/j.jhep.2020.04.006]

36 **Sonzogni A**, Previtali G, Seghezzi M, Grazia Alessio M, Gianatti A, Licini L, Morotti D, Zerbi P, Carsana L, Rossi R, Lauri E, Pellegrinelli A, Nebuloni M. Liver histopathology in severe COVID 19 respiratory failure is suggestive of vascular alterations. *Liver Int* 2020; **40**: 2110-2116 [PMID: 32654359 DOI: 10.1111/liv.14601]

37 **Giubelan LI**, Dumitrescu F, Stoian AC, Dragonu L. Analysis of the First 300 Cases of SARS CoV2 Infection from the Infection Disease Clinic of Craiova, Romania. *Curr Health Sci J* 2021; **47**: 28-32 [PMID: 34211744 DOI: 10.12865/CHSJ.47.01.05]

38 **Green WD**, Beck MA. Obesity Impairs the Adaptive Immune Response to Influenza Virus. *Ann Am Thorac Soc* 2017; **14**: S406-S409 [PMID: 29161078 DOI: 10.1513/AnnalsATS.201706-447AW]

39 **Iruzubieta P**, Medina JM, Fernández-López R, Crespo J, de la Cruz F. A Role for Gut Microbiome Fermentative Pathways in Fatty Liver Disease Progression. *J Clin Med* 2020; **9** [PMID: 32392712 DOI: 10.3390/jcm9051369]

40 **Kamyari N**, Soltanian AR, Mahjub H, Moghimbeigi A. Diet, Nutrition, Obesity, and Their Implications for COVID-19 Mortality: Development of a Marginalized Two-Part Model for Semicontinuous Data. *JMIR Public Health Surveill* 2021; **7**: e22717 [PMID: 33439850 DOI: 10.2196/22717]

41 **Siracusa F**, Schaltenberg N, Villablanca EJ, Huber S, Gagliani N. Dietary Habits and Intestinal Immunity: From Food Intake to CD4+ T *H* Cells. *Front Immunol* 2018; **9**: 3177 [PMID: 30697217 DOI: 10.3389/fimmu.2018.03177]

42 **Connaughton RM**, McMorrow AM, McGillicuddy FC, Lithander FE, Roche HM. Impact of anti-inflammatory nutrients on obesity-associated metabolic-inflammation from childhood through to adulthood. *Proc Nutr Soc* 2016; **75**: 115-124 [PMID: 26934951 DOI: 10.1017/S0029665116000070]

43 **Aguila EJT**, Cua IHY, Fontanilla JAC, Yabut VLM, Causing MFP. Gastrointestinal Manifestations of COVID-19: Impact on Nutrition Practices. *Nutr Clin Pract* 2020; **35**: 800-805 [PMID: 32668037 DOI: 10.1002/ncp.10554]

44 **Plauth M**, Bernal W, Dasarathy S, Merli M, Plank LD, Schütz T, Bischoff SC. ESPEN guideline on clinical nutrition in liver disease. *Clin Nutr* 2019; **38**: 485-521 [PMID: 30712783 DOI: 10.1016/j.clnu.2018.12.022]

45 **Nanchal R**, Subramanian R, Karvellas CJ, Hollenberg SM, Peppard WJ, Singbartl K, Truwit J, Al-Khafaji AH, Killian AJ, Alquraini M, Alshammari K, Alshamsi F, Belley-Cote E, Cartin-Ceba R, Dionne JC, Galusca DM, Huang DT, Hyzy RC, Junek M, Kandiah P, Kumar G, Morgan RL, Morris PE, Olson JC, Sieracki R, Steadman R, Taylor B, Alhazzani W. Guidelines for the Management of Adult Acute and Acute-on-Chronic Liver Failure in the ICU: Cardiovascular, Endocrine, Hematologic, Pulmonary, and Renal Considerations. *Crit Care Med* 2020; **48**: e173-e191 [PMID: 32058387 DOI: 10.1097/CCM.0000000000004192]

46 **Martindale R**, Patel JJ, Taylor B, Arabi YM, Warren M, McClave SA. Nutrition Therapy in Critically Ill Patients With Coronavirus Disease 2019. *JPEN J Parenter Enteral Nutr* 2020; **44**: 1174-1184 [PMID: 32462719 DOI: 10.1002/jpen.1930]

47 **Thibault R**, Coëffier M, Joly F, Bohé J, Schneider SM, Déchelotte P. How the Covid-19 epidemic is challenging our practice in clinical nutrition-feedback from the field. *Eur J Clin Nutr* 2021; **75**: 407-416 [PMID: 32939042 DOI: 10.1038/s41430-020-00757-6]

48 **De Waele E**, Malbrain MLNG, Spapen H. Nutrition in Sepsis: A Bench-to-Bedside Review. *Nutrients* 2020; **12** [PMID: 32024268 DOI: 10.3390/nu12020395]

49 **Patel JJ**, Rice T, Heyland DK. Safety and Outcomes of Early Enteral Nutrition in Circulatory Shock. *JPEN J Parenter Enteral Nutr* 2020; **44**: 779-784 [PMID: 32052460 DOI: 10.1002/jpen.1793]

50 **Hotchkiss RS**, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. *Nat Rev Immunol* 2013; **13**: 862-874 [PMID: 24232462 DOI: 10.1038/nri3552]

51 **Patel JJ**, Martindale RG, McClave SA. Relevant Nutrition Therapy in COVID-19 and the Constraints on Its Delivery by a Unique Disease Process. *Nutr Clin Pract* 2020; **35**: 792-799 [PMID: 32786117 DOI: 10.1002/ncp.10566]

52 **Madnawat H**, Welu AL, Gilbert EJ, Taylor DB, Jain S, Manithody C, Blomenkamp K, Jain AK. Mechanisms of Parenteral Nutrition-Associated Liver and Gut Injury. *Nutr Clin Pract* 2020; **35**: 63-71 [PMID: 31872510 DOI: 10.1002/ncp.10461]

53 **Denton C**, Price A, Friend J, Manithody C, Blomenkamp K, Westrich M, Kakarla V, Phillips W, Krebs J, Abraham Munoz S, Osei H, Jain AK. Role of the Gut⁻Liver Axis in Driving Parenteral Nutrition-Associated Injury. *Children (Basel)* 2018; **5** [PMID: 30257520 DOI: 10.3390/children5100136]

54 **Omata J**, Fukatsu K, Murakoshi S, Noguchi M, Miyazaki H, Moriya T, Okamoto K, Fukazawa S, Akase T, Saitoh D, Mochizuki H, Yamamoto J, Hase K. Enteral refeeding rapidly restores PN-induced reduction of hepatic mononuclear cell number through recovery of small intestine and portal vein blood flows. *JPEN J Parenter Enteral Nutr* 2009; **33**: 618-25; discussion 626 [PMID: 19675300 DOI: 10.1177/0148607109336598]

55 **Vennard KC**, Selen DJ, Gilbert MP. The management of hyperglycemia in noncritically ill hospitalized patients treated with continuous enteral or parenteral nutrition. *Endocr Pract* 2018; **24**: 900-906 [PMID: 30035626 DOI: 10.4158/EP-2018-0150]

56 **Sardu C**, D'Onofrio N, Balestrieri ML, Barbieri M, Rizzo MR, Messina V, Maggi P, Coppola N, Paolisso G, Marfella R. Outcomes in Patients With Hyperglycemia Affected by COVID-19: Can We Do More on Glycemic Control? *Diabetes Care* 2020; **43**: 1408-1415 [PMID: 32430456 DOI: 10.2337/dc20-0723]

57 **Liu SP**, Zhang Q, Wang W, Zhang M, Liu C, Xiao X, Liu Z, Hu WM, Jin P. Hyperglycemia is a strong predictor of poor prognosis in COVID-19. *Diabetes Res Clin Pract* 2020; **167**: 108338 [PMID: 32712122 DOI: 10.1016/j.diabres.2020.108338]

58 **Khadge S**, Sharp JG, Thiele GM, McGuire TR, Klassen LW, Duryee MJ, Britton HC, Dafferner AJ, Beck J, Black PN, DiRusso CC, Talmadge J. Dietary omega-3 and omega-6 polyunsaturated fatty acids modulate hepatic pathology. *J Nutr Biochem* 2018; **52**: 92-102 [PMID: 29175671 DOI: 10.1016/j.jnutbio.2017.09.017]

59 **Geervliet E**, Bansal R. Matrix Metalloproteinases as Potential Biomarkers and Therapeutic Targets in Liver Diseases. *Cells* 2020; **9** [PMID: 32414178 DOI: 10.3390/cells9051212]

60 **Thibault R**, Seguin P, Tamion F, Pichard C, Singer P. Nutrition of the COVID-19 patient in the intensive care unit (ICU): a practical guidance. *Crit Care* 2020; **24**: 447 [PMID: 32684170 DOI: 10.1186/s13054-020-03159-z]

61 **Shuja A**, Malespin M, Scolapio J. Nutritional Considerations in Liver Disease. *Gastroenterol Clin North Am* 2018; **47**: 243-252 [PMID: 29413017 DOI: 10.1016/j.gtc.2017.09.010]

62 **European Association for the Study of the Liver**. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. *J Hepatol* 2019; **70**: 172-193 [PMID: 30144956 DOI: 10.1016/j.jhep.2018.06.024]

63 **Paynter S**, Ware RS, Lucero MG, Tallo V, Nohynek H, Weinstein P, Williams G, Sly PD, Simões EA. Malnutrition: a risk factor for severe respiratory syncytial virus infection and hospitalization. *Pediatr Infect Dis J* 2014; **33**: 267-271 [PMID: 24168980 DOI: 10.1097/INF.0000000000000096]

64 **Wintergerst ES**, Maggini S, Hornig DH. Contribution of selected vitamins and trace elements to immune function. *Ann Nutr Metab* 2007; **51**: 301-323 [PMID: 17726308 DOI: 10.1159/000107673]

65 **Martineau AR**, Jolliffe DA, Hooper RL, Greenberg L, Aloia JF, Bergman P, Dubnov-Raz G, Esposito S, Ganmaa D, Ginde AA, Goodall EC, Grant CC, Griffiths CJ, Janssens W, Laaksi I, Manaseki-Holland S, Mauger D, Murdoch DR, Neale R, Rees JR, Simpson S Jr, Stelmach I, Kumar GT, Urashima M, Camargo CA Jr. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. *BMJ* 2017; **356**: i6583 [PMID: 28202713 DOI: 10.1136/bmj.i6583]

66 **Cai C**, Koch B, Morikawa K, Suda G, Sakamoto N, Rueschenbaum S, Akhras S, Dietz J, Hildt E, Zeuzem S, Welsch C, Lange CM. Macrophage-Derived Extracellular Vesicles Induce Long-Lasting Immunity Against Hepatitis C Virus Which Is Blunted by Polyunsaturated Fatty Acids. *Front Immunol* 2018; **9**: 723 [PMID: 29706960 DOI: 10.3389/fimmu.2018.00723]

67 **Jayawardena R**, Sooriyaarachchi P, Chourdakis M, Jeewandara C, Ranasinghe P. Enhancing immunity in viral infections, with special emphasis on COVID-19: A review. *Diabetes Metab Syndr* 2020; **14**: 367-382 [PMID: 32334392 DOI: 10.1016/j.dsx.2020.04.015]

68 **Wu D**, Lewis ED, Pae M, Meydani SN. Nutritional Modulation of Immune Function: Analysis of Evidence, Mechanisms, and Clinical Relevance. *Front Immunol* 2018; **9**: 3160 [PMID: 30697214 DOI: 10.3389/fimmu.2018.03160]

69 **Jovic TH**, Ali SR, Ibrahim N, Jessop ZM, Tarassoli SP, Dobbs TD, Holford P, Thornton CA, Whitaker IS. Could Vitamins Help in the Fight Against COVID-19? *Nutrients* 2020; **12** [PMID: 32842513 DOI: 10.3390/nu12092550]

70 **Semba RD**. Vitamin A and immunity to viral, bacterial and protozoan infections. *Proc Nutr Soc* 1999; **58**: 719-727 [PMID: 10604208 DOI: 10.1017/s0029665199000944]

71 **Trottier C**, Colombo M, Mann KK, Miller WH Jr, Ward BJ. Retinoids inhibit measles virus through a type I IFN-dependent bystander effect. *FASEB J* 2009; **23**: 3203-3212 [PMID: 19447880 DOI: 10.1096/fj.09-129288]

72 **Jee J**, Hoet AE, Azevedo MP, Vlasova AN, Loerch SC, Pickworth CL, Hanson J, Saif LJ. Effects of dietary vitamin A content on antibody responses of feedlot calves inoculated intramuscularly with an inactivated bovine coronavirus vaccine. *Am J Vet Res* 2013; **74**: 1353-1362 [PMID: 24066921 DOI: 10.2460/ajvr.74.10.1353]

73 **Keil SD**, Bowen R, Marschner S. Inactivation of Middle East respiratory syndrome coronavirus (MERS-CoV) in plasma products using a riboflavin-based and ultraviolet light-based photochemical treatment. *Transfusion* 2016; **56**: 2948-2952 [PMID: 27805261 DOI: 10.1111/trf.13860]

74 **Kyme P**, Thoennissen NH, Tseng CW, Thoennissen GB, Wolf AJ, Shimada K, Krug UO, Lee K, Müller-Tidow C, Berdel WE, Hardy WD, Gombart AF, Koeffler HP, Liu GY. C/EBPε mediates nicotinamide-enhanced clearance of Staphylococcus aureus in mice. *J Clin Invest* 2012; **122**: 3316-3329 [PMID: 22922257 DOI: 10.1172/JCI62070]

75 **Jones HD**, Yoo J, Crother TR, Kyme P, Ben-Shlomo A, Khalafi R, Tseng CW, Parks WC, Arditi M, Liu GY, Shimada K. Correction: Nicotinamide exacerbates hypoxemia in ventilator-induced lung injury independent of neutrophil infiltration. *PLoS One* 2015; **10**: e0128735 [PMID: 25996479 DOI: 10.1371/journal.pone.0128735]

76 **Kandeel M**, Al-Nazawi M. Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease. *Life Sci* 2020; **251**: 117627 [PMID: 32251634 DOI: 10.1016/j.lfs.2020.117627]

77 **Rocco A**, Compare D, Coccoli P, Esposito C, Di Spirito A, Barbato A, Strazzullo P, Nardone G. Vitamin B12 supplementation improves rates of sustained viral response in patients chronically infected with hepatitis C virus. *Gut* 2013; **62**: 766-773 [PMID: 22810757 DOI: 10.1136/gutjnl-2012-302344]

78 **Hemilä H**. Vitamin C and SARS coronavirus. *J Antimicrob Chemother* 2003; **52**: 1049-1050 [PMID: 14613951 DOI: 10.1093/jac/dkh002]

79 **Field CJ**, Johnson IR, Schley PD. Nutrients and their role in host resistance to infection. *J Leukoc Biol* 2002; **71**: 16-32 [PMID: 11781377]

80 **Myint PK**, Wilson AM, Clark AB, Luben RN, Wareham NJ, Khaw KT. Plasma vitamin C concentrations and risk of incident respiratory diseases and mortality in the European Prospective Investigation into Cancer-Norfolk population-based cohort study. *Eur J Clin Nutr* 2019; **73**: 1492-1500 [PMID: 30705384 DOI: 10.1038/s41430-019-0393-1]

81 **Grant WB**, Lahore H, McDonnell SL, Baggerly CA, French CB, Aliano JL, Bhattoa HP. Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths. *Nutrients* 2020; **12** [PMID: 32252338 DOI: 10.3390/nu12040988]

82 **Hemilä H**. Vitamin E and the risk of pneumonia: using the I 2 statistic to quantify heterogeneity within a controlled trial. *Br J Nutr* 2016; **116**: 1530-1536 [PMID: 27780487 DOI: 10.1017/S0007114516003408]

83 **Nonnecke BJ**, McGill JL, Ridpath JF, Sacco RE, Lippolis JD, Reinhardt TA. Acute phase response elicited by experimental bovine diarrhea virus (BVDV) infection is associated with decreased vitamin D and E status of vitamin-replete preruminant calves. *J Dairy Sci* 2014; **97**: 5566-5579 [PMID: 25022687 DOI: 10.3168/jds.2014-8293]

84 **Beck MA**, Shi Q, Morris VC, Levander OA. Rapid genomic evolution of a non-virulent coxsackievirus B3 in selenium-deficient mice results in selection of identical virulent isolates. *Nat Med* 1995; **1**: 433-436 [PMID: 7585090 DOI: 10.1038/nm0595-433]

85 **Ma X**, Bi S, Wang Y, Chi X, Hu S. Combined adjuvant effect of ginseng stem-leaf saponins and selenium on immune responses to a live bivalent vaccine of Newcastle disease virus and infectious bronchitis virus in chickens. *Poult Sci* 2019; **98**: 3548-3556 [PMID: 31220864 DOI: 10.3382/ps/pez207]

86 **Hoffmann PR**, Berry MJ. The influence of selenium on immune responses. *Mol Nutr Food Res* 2008; **52**: 1273-1280 [PMID: 18384097 DOI: 10.1002/mnfr.200700330]

87 **Taylor EW**, Ruzicka JA, Premadasa L, Zhao L. Cellular Selenoprotein mRNA Tethering *via* Antisense Interactions with Ebola and HIV-1 mRNAs May Impact Host Selenium Biochemistry. *Curr Top Med Chem* 2016; **16**: 1530-1535 [PMID: 26369818 DOI: 10.2174/1568026615666150915121633]

88 **Hurwitz BE**, Klaus JR, Llabre MM, Gonzalez A, Lawrence PJ, Maher KJ, Greeson JM, Baum MK, Shor-Posner G, Skyler JS, Schneiderman N. Suppression of human immunodeficiency virus type 1 viral load with selenium supplementation: a randomized controlled trial. *Arch Intern Med* 2007; **167**: 148-154 [PMID: 17242315 DOI: 10.1001/archinte.167.2.148]

89 **Mahmoodpoor A**, Hamishehkar H, Sanaie S, Behruzizad N, Iranpour A, Koleini E, Nader ND. Antioxidant reserve of the lungs and ventilator-associated pneumonia: A clinical trial of high dose selenium in critically ill patients. *J Crit Care* 2018; **44**: 357-362 [PMID: 29288963 DOI: 10.1016/j.jcrc.2017.12.016]

90 **Shittu MO**, Afolami OI. Improving the efficacy of Chloroquine and Hydroxychloroquine against SARS-CoV-2 may require Zinc additives - A better synergy for future COVID-19 clinical trials. *Infez Med* 2020; **28**: 192-197 [PMID: 32335560]

91 **te Velthuis AJ**, van den Worm SH, Sims AC, Baric RS, Snijder EJ, van Hemert MJ. Zn(2+) inhibits coronavirus and arterivirus RNA polymerase activity *in vitro* and zinc ionophores block the replication of these viruses in cell culture. *PLoS Pathog* 2010; **6**: e1001176 [PMID: 21079686 DOI: 10.1371/journal.ppat.1001176]

92 **Awotiwon AA**, Oduwole O, Sinha A, Okwundu CI. Zinc supplementation for the treatment of measles in children. *Cochrane Database Syst Rev* 2017; **6**: CD011177 [PMID: 28631310 DOI: 10.1002/14651858.CD011177.pub3]

93 **Santos HO**, Tinsley GM, da Silva GAR, Bueno AA. Pharmaconutrition in the Clinical Management of COVID-19: A Lack of Evidence-Based Research But Clues to Personalized Prescription. *J Pers Med* 2020; **10** [PMID: 32992693 DOI: 10.3390/jpm10040145]

94 **Dushianthan A**, Cusack R, Burgess VA, Grocott MP, Calder PC. Immunonutrition for acute respiratory distress syndrome (ARDS) in adults. *Cochrane Database Syst Rev* 2019; **1**: CD012041 [PMID: 30677127 DOI: 10.1002/14651858.CD012041.pub2]

95 **Bischoff SC**, Bernal W, Dasarathy S, Merli M, Plank LD, Schütz T, Plauth M. ESPEN practical guideline: Clinical nutrition in liver disease. *Clin Nutr* 2020; **39**: 3533-3562 [PMID: 33213977 DOI: 10.1016/j.clnu.2020.09.001]

96 **Mayo-Wilson E**, Imdad A, Herzer K, Yakoob MY, Bhutta ZA. Vitamin A supplements for preventing mortality, illness, and blindness in children aged under 5: systematic review and meta-analysis. *BMJ* 2011; **343**: d5094 [PMID: 21868478 DOI: 10.1136/bmj.d5094]

97 **Aluisio AR**, Perera SM, Yam D, Garbern S, Peters JL, Abel L, Cho DK, Kennedy SB, Massaquoi M, Sahr F, Brinkmann S, Locks L, Liu T, Levine AC. Vitamin A Supplementation Was Associated with Reduced Mortality in Patients with Ebola Virus Disease during the West African Outbreak. *J Nutr* 2019; **149**: 1757-1765 [PMID: 31268140 DOI: 10.1093/jn/nxz142]

98 **International Society for Immunonutrition**. ISIN Position Statement on Nutrition, Immunity and COVID-19. [cited 25 May 2020]. In: International Society for Immunonutrition [Internet]. Available from: https://immunonutrition-isin.org/docs/isinComunicadoCovid19.pdf

99 **Andreone P**, Fiorino S, Cursaro C, Gramenzi A, Margotti M, Di Giammarino L, Biselli M, Miniero R, Gasbarrini G, Bernardi M. Vitamin E as treatment for chronic hepatitis B: results of a randomized controlled pilot trial. *Antiviral Res* 2001; **49**: 75-81 [PMID: 11248360 DOI: 10.1016/s0166-3542(00)00141-8]

100 **Look MP**, Gerard A, Rao GS, Sudhop T, Fischer HP, Sauerbruch T, Spengler U. Interferon/antioxidant combination therapy for chronic hepatitis C--a controlled pilot trial. *Antiviral Res* 1999; **43**: 113-122 [PMID: 10517313 DOI: 10.1016/s0166-3542(99)00041-8]

101 **Chen L**, Li J, Luo C, Liu H, Xu W, Chen G, Liew OW, Zhu W, Puah CM, Shen X, Jiang H. Binding interaction of quercetin-3-beta-galactoside and its synthetic derivatives with SARS-CoV 3CL(pro): structure-activity relationship studies reveal salient pharmacophore features. *Bioorg Med Chem* 2006; **14**: 8295-8306 [PMID: 17046271 DOI: 10.1016/j.bmc.2006.09.014]

102 **Heinz SA**, Henson DA, Austin MD, Jin F, Nieman DC. Quercetin supplementation and upper respiratory tract infection: A randomized community clinical trial. *Pharmacol Res* 2010; **62**: 237-242 [PMID: 20478383 DOI: 10.1016/j.phrs.2010.05.001]

103 **Clark KJ**, Grant PG, Sarr AB, Belakere JR, Swaggerty CL, Phillips TD, Woode GN. An *in vitro* study of theaflavins extracted from black tea to neutralize bovine rotavirus and bovine coronavirus infections. *Vet Microbiol* 1998; **63**: 147-157 [PMID: 9850995 DOI: 10.1016/s0378-1135(98)00242-9]

104 **Lin SC**, Ho CT, Chuo WH, Li S, Wang TT, Lin CC. Effective inhibition of MERS-CoV infection by resveratrol. *BMC Infect Dis* 2017; **17**: 144 [PMID: 28193191 DOI: 10.1186/s12879-017-2253-8]

105 **Wen CC**, Kuo YH, Jan JT, Liang PH, Wang SY, Liu HG, Lee CK, Chang ST, Kuo CJ, Lee SS, Hou CC, Hsiao PW, Chien SC, Shyur LF, Yang NS. Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus. *J Med Chem* 2007; **50**: 4087-4095 [PMID: 17663539 DOI: 10.1021/jm070295s]

106 **Wu YH**, Tseng CP, Cheng ML, Ho HY, Shih SR, Chiu DT. Glucose-6-phosphate dehydrogenase deficiency enhances human coronavirus 229E infection. *J Infect Dis* 2008; **197**: 812-816 [PMID: 18269318 DOI: 10.1086/528377]

107 **Food and Nutrition Board, Institute of Medicine**. New dietary reference intakes set for energy, carbohydrates, fiber, fat, fatty adds, cholesterol, proteins, and amino acids. [cited 22 May 2020]. In: Food and Nutrition Board, Institute of Medicine [Internet]. Available from: https://www.nal.usda.gov/sites/default/files/fnic\_uploads/energy\_full\_report.pdf

**Footnotes**

**Conflict-of-interest statement:** The authors declare that this research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** May 13, 2021

**First decision:** July 18, 2021

**Article in press:** December 22, 2021

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Brazil

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Chi G, El-Gendy HA **S-Editor:** Gao CC **L-Editor:** A **P-Editor:** Gao CC

**Figure Legends**

****

**Figure 1 Health, diet and lifestyle practices associated with clinical outcomes in SARS-CoV-2 infection.** Individuals suffering with systemic inflammatory background associated with overweight, obesity, diabetes, heart disease and hypertension, and chronic liver disease, as well as elderly individuals, are more susceptible to develop the most severe forms of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Chronic consumption of typical westernised diets (WD) diets, which are rich in saturated fat, carbohydrates with high glycaemic index, and low in fresh fruits and vegetables, is relatively common amongst individuals who present worsened clinical outcomes. A typical WD dietary pattern features low nutritional value, facilitating deficiencies of vitamins, minerals, polyunsaturated fatty acids and bioactive compounds such as resveratrol, quercetin, catechins, curcumin and lipoic acid, amongst others. Nutritional deficit can facilitate the exacerbation of oxidative stress, inflammation and insulin resistance, with consequent disturbances in the innate and adaptive immune response, resulting in suppression of the immune response and greater susceptibility to infections. Coronavirus infection is usually associated with a “cytokine storm”, intense inflammation, leukopenia and lymphocytopenia. Individuals with preestablished pro-inflammatory background and impaired immune system due to poor diet are at greater risk of evolving more rapidly to the more severe forms of SARS-CoV-2 infection[12,37,81]. SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; COVID-19: Coronavirus disease 2019.

**Table 1 Nutritional recommendations for patients suffering with chronic hepatic disease[44,45,95]**

|  |  |  |  |
| --- | --- | --- | --- |
| **Nutrients** | **ESPEN 2019** | **ESPEN 2020** | **Critical care medicine 2020** |
| **Non-obese** | **Obese** |
| Calories | 30 kcal/kg per day to 35 kcal/kg per day | 30 kcal/kg per day to 35 kcal/kg per day | 25 kcal/kg per day | 30 kcal/kg per day to 35 kcal/kg per day; Glycaemic target at 110 mg/dL to 180 mg/dL |
| Protein | 1.2 g/kg per day to 1.5 g/kg per day | 1.2 g/kg per day to 1.5 g/kg per day | 2.0 g/kg per day to 2.5 g/kg per day | 1.5 g/kg per day to 2.0 g/kg per day |
| EN + BCAA | 0.20 g/kg to 0.25 g/kg | Not routinely recommended | 0.2 g/kg to 0.25 g/kg |

BCAA: Branched chain amino acids; EN: Enteral nutrition.

**Table 2 Vitamins, nutraceuticals and bioactive compounds in supporting therapies for coronaviruses, including severe acute respiratory syndrome coronavirus, Middle East respiratory syndrome coronavirus, bovine and avian coronavirus[107]**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Nutrients and bioactive compounds (RDA, when available)** | **Effects in humans1** | **Dose** | **Antiviral action** | **Ref.** |
| Vitamin A, 2RDA: 700-900 μg/d, UL: 3000 μg/d or 10.000 IU | Yes (Measles, Ebola) | Until 3000 IU μg/d (children from 6 mo to 11 mo) and 60000 μg/d children 1-5 yr; Adults: 60000 μg in 2 consecutive days | Measles, Ebola, Bovine coronavirus | Mayo-Wilson *et al*[96], 2011; Aluisio *et al*[97], 2019; Jee *et al*[72], 2013 |
| Vitamin B2, 2RDA: 1.1-1.3 mg/d, UL: ND (not determined) | No | 2-3 times RDA3 | MERS-CoV + UV radiation (antiseptic) | Keil *et al*[73], 2016 |
| Vitamin B12, 2RDA: 2,4 μg/d, UL: ND | Yes | 5000 μg IM (intramuscular) monthly | SARS-CoV-2 (molecular modelling), HCV | Kandeel *et al*[76], 2020; Rocco *et al*[77], 2013 |
| Vitamin C, 2RDA: 75-90 mg/d, UL: 2000 mg/d | Yes (ICU, pneumonia) | 1-3 g/d; Inpatient: 50 mg/kg IV (intravenous) 6/6 h for 4 d; Elderly: 200 mg/d-2 g/d | Pneumonia, MERS-CoV | Hemilä[78], 2003; Field *et al*[79], 2002; Myint *et al*[80], 2019; International Society for Immunonutrition[98] |
| Vitamin D, 2RDA: 5-15 μg/d, UL: 50 μg/d or 2000 UI | Yes (pneumonia, acute upper respiratory infection) | 30 μg/d; Or Bolus: 2500-5000 μg/mo; Elderly: 10-100μg/d | Pneumonia, UAI, bovine coronavirus | Martineau *et al*[65], 2017; Jayawardena *et al*[67], 2020; Grant *et al*[81], 2020; International Society for Immunonutrition[98] |
| Vitamin E, 2RDA: 15 mg/d, UL: 1000 mg/d or 1490 UI | No | 300 mg 2xd for 3 mo or 365 mg/d for 6 mo; Elderly: (134- 800 mg/d) | Bovine coronavirus, Coxsackie | Andreone *et al*[99], 2001; Look *et al*[100], 1999; Nonnecke *et al*[83], 2014; International Society for Immunonutrition[98] |
| Zinc, 2RDA: 8-11 mg/d, UL: 40 mg/d | Yes (measles, SARS-CoV) | 75-100 mg/d; Elderly: 30-220 mg/d | Measles, SARS-CoV | Awotiwon *et al*[92], 2017; te Velthuis *et al*[91], 2010; International Society for Immunonutrition[98] |
| Selenium, 2RDA: 55 μg/d, UL: 400 μg/d | Yes (influenza) | 200 μg/d | Influenza, Avian coronavirus | Hoffmann and Berry[86], 2008; Ma *et al*[85], 2019 |
| Omega-3 | Yes (influenza) | 1-3 g/d3 | Influenza, HCV | Cai *et al*[66], 2018 |
| Quercetin | No | 1 g/d | SARS-Cov (*in vitro*), IVAS | Chen *et al*[101], 2006; Heinz *et al*[102], 2010 |
| Green tea/catechins (EGCG) | No | 4 cups/d or 225 mg de EGCG4 | Bovine coronavirus (*in vitro*) | Clark *et al*[103], 1998 |
| Resveratrol | No | 100-150 mg 2 × d3 | MERS-CoV (*in vitro*) | Lin *et al*[104], 2017 |
| Curcumin | No | 0.5-1 g/d3 | SARS-CoV(*in vitro*) | Wen *et al*[105], 2007 |
| Lipoic acid | No | 600 mg/d3 | Human coronavirus 229E (*in vitro*) | Wu *et al*[106], 2008 |

1We did not find any work related to this substance and anti-viral or anti-infectious action in humans. 2For adult patients, according to age group and gender. 3Usual dose employed in clinical practice. 4Epigallocatechin. RDA: Recommended dietary allowance; UAI: Upper airway infection; UL: Tolerable upper intake levels; ICU: Intensive care unit.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**